

CASTLIGHT HEALTH, INC.
Form 4
March 19, 2014

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287
Expires: January 31, 2015
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
VENROCK ASSOCIATES V LP

2. Issuer Name and Ticker or Trading Symbol
CASTLIGHT HEALTH, INC.
[CSLT]

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

(Last) (First) (Middle)

3. Date of Earliest Transaction
(Month/Day/Year)

___ Director ___X___ 10% Owner
___ Officer (give title below) ___ Other (specify below)

C/O VENROCK, 3340 HILLVIEW AVENUE

03/19/2014

(Street)

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)
___ Form filed by One Reporting Person
X Form filed by More than One Reporting Person

PALO ALTO, CA 94304

(City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Ownership (Instr. 4) | | |
|---------------------------------|--------------------------------------|--|--------------------------------|---|---|--|-----------------------------------|-----|-------|
| | | | | (A) or (D) | Code | V | Amount | (D) | Price |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative | 2. Conversion | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if | 4. Transaction | 5. Number of Derivative Securities Acquired (A) or | 6. Date Exercisable and Expiration Date | 7. Title and Underlying |
|------------------------|---------------|--------------------------------------|-------------------------------|----------------|--|---|-------------------------|
|------------------------|---------------|--------------------------------------|-------------------------------|----------------|--|---|-------------------------|

Edgar Filing: CASTLIGHT HEALTH, INC. - Form 4

| Security (Instr. 3) | or Exercise Price of Derivative Security | any (Month/Day/Year) | Code (Instr. 8) | Disposed of (D) | | (Month/Day/Year) | | (Instr. 3 and 5) | |
|---|---|-------------------------|--------------------|-----------------|------------------------------|------------------|-------------------------------|-------------------------------|---|
| | | | | Code V | (A) | (D) | Date Exercisable | | Expiration Date |
| Series A Convertible Preferred Stock | \$ 0 ⁽¹⁾ | 03/19/2014 | C | | 3,906,730 | | ⁽¹⁾ | ⁽¹⁾ | Class A Common Stock ⁽²⁾ ⁽³⁾ |
| Series A-1 Convertible Preferred Stock | \$ 0 ⁽¹⁾ | 03/19/2014 | C | | 6,630,686 | | ⁽¹⁾ | ⁽¹⁾ | Class A Common Stock ⁽²⁾ ⁽³⁾ |
| Series B Convertible Preferred Stock | \$ 0 ⁽¹⁾ | 03/19/2014 | C | | 3,617,117 | | ⁽¹⁾ | ⁽¹⁾ | Class A Common Stock ⁽²⁾ ⁽³⁾ |
| Series C Convertible Preferred Stock | \$ 0 ⁽¹⁾ | 03/19/2014 | C | | 924,373 | | ⁽¹⁾ | ⁽¹⁾ | Class A Common Stock ⁽²⁾ ⁽³⁾ |
| Series D Convertible Preferred Stock | \$ 0 ⁽¹⁾ | 03/19/2014 | C | | 303,650 | | ⁽¹⁾ | ⁽¹⁾ | Class A Common Stock ⁽²⁾ ⁽³⁾ |
| Class A Common Stock | \$ 0 ⁽²⁾ ⁽³⁾ | 03/19/2014 | C | | 15,382,556 ⁽¹⁾ | | ⁽²⁾ ⁽³⁾ | ⁽²⁾ ⁽³⁾ | Class B Common Stock ⁽³⁾ |

Reporting Owners

| Reporting Owner Name / Address | Relationships | | | |
|---|---------------|-----------|---------|-------|
| | Director | 10% Owner | Officer | Other |
| VENROCK ASSOCIATES V LP C/O VENROCK 3340 HILLVIEW AVENUE PALO ALTO, CA 94304 | | X | | |
| VENROCK PARTNERS V L P C/O VENROCK 3340 HILLVIEW AVENUE PALO ALTO, CA 94304 | | X | | |
| Venrock Entrepreneurs Fund V, L.P. C/O VENROCK 3340 HILLVIEW AVENUE | | X | | |

PALO ALTO, CA 94304

Venrock Management V, LLC

C/O VENROCK

3340 HILLVIEW AVENUE

PALO ALTO, CA 94304

X

Venrock Partners Management V, LLC

C/O VENROCK

3340 HILLVIEW AVENUE

PALO ALTO, CA 94304

X

VEF Management V, LLC

C/O VENROCK

3340 HILLVIEW AVENUE

PALO ALTO, CA 94304

X

Signatures

/s/ David L. Stepp, authorized
signatory

03/19/2014

__Signature of Reporting Person

Date

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

In connection with the consummation of the Issuer's initial public offering (the "IPO") on March 19, 2014, each share of Convertible

- (1) Preferred Stock automatically converted into one (1) share of Class A Common Stock for no additional consideration. All shares of Class A Common Stock issued upon conversion were aggregated.

Each share of Class A Common Stock is convertible, at any time at the option of the holder, into one (1) share of Class B Common Stock.

- (2) In addition, each share of Class A Common Stock will convert automatically into one (1) share of Class B Common Stock upon the transfer, whether or not for value, that occurs after the closing of the IPO to any transferee who is not a "Permitted Transferee", as defined in the Issuer's Restated Certificate of Incorporation in effect as of the date hereof. The shares of Class A Common Stock have no expiration date.

- (3) Each share of the Issuer's Class A Common Stock will convert automatically into one (1) share of Class B Common Stock upon the earliest to occur of the following: (a) the first date on which the number of shares of Class A Common Stock then outstanding is less than 15,340,384 shares, (b) March 19, 2024, or (c) a time and date approved in writing by holders of at least a majority of the then-outstanding shares of Class A Common Stock. The shares of Class A Common Stock and Class B Common Stock have no expiration date.

- (4) Venrock Associates V, L.P. ("VA5") held an aggregate of 3,525,043 shares, Venrock Partners V, L.P. ("VP5") held an aggregate of 298,865 shares and Venrock Entrepreneurs Fund V, L.P. ("VEF5") held an aggregate of 82,822 shares. Venrock Management V, LLC, VEF Management V, LLC and Venrock Partners Management V, LLC (collectively, the "Venrock GP Entities") are the sole general partners of VA5, VEF5 and VP5 (collectively, the "Funds"), respectively, and have voting and investment power over the shares held by the Funds. Each of the Venrock GP Entities disclaims beneficial ownership of the shares held by the Funds, except to the extent of their respective indirect pecuniary interests therein.

- (5) VA5 held an aggregate of 5,982,868 shares, VP5 held an aggregate of 507,247 shares and VEF5 held an aggregate of 140,571 shares. The Venrock GP Entities are the sole general partners of the Funds, and have voting and investment power over the shares held by the Funds. Each of the Venrock GP Entities disclaims beneficial ownership of the shares held by the Funds, except to the extent of their respective indirect pecuniary interests therein.

- (6) VA5 held an aggregate of 3,263,725 shares, VP5 held an aggregate of 276,710 shares and VEF5 held an aggregate of 76,682 shares. The Venrock GP Entities are the sole general partners of the Funds, and have voting and investment power over the shares held by the Funds. Each of the Venrock GP Entities disclaims beneficial ownership of the shares held by the Funds, except to the extent of their respective indirect pecuniary interests therein.

- (7) VA5 held an aggregate of 834,062 shares, VP5 held an aggregate of 70,714 shares and VEF5 held an aggregate of 19,597 shares. The Venrock GP Entities are the sole general partners of the Funds, and have voting and investment power over the shares held by the Funds. Each of the Venrock GP Entities disclaims beneficial ownership of the shares held by the Funds, except to the extent of their respective

Edgar Filing: CASTLIGHT HEALTH, INC. - Form 4

indirect pecuniary interests therein.

- (8) VA5 held an aggregate of 273,983 shares, VP5 held an aggregate of 23,230 shares and VEF5 held an aggregate of 6,437 shares. The Venrock GP Entities are the sole general partners of the Funds, and have voting and investment power over the shares held by the Funds. Each of the Venrock GP Entities disclaims beneficial ownership of the shares held by the Funds, except to the extent of their respective indirect pecuniary interests therein.

- (9) VA5 holds an aggregate of 14,047,522 shares, VP5 holds an aggregate of 1,190,996 shares and VEF5 holds an aggregate of 330,053 shares. The Venrock GP Entities are the sole general partners of the Funds, and have voting and investment power over the shares held by the Funds. Each of the Venrock GP Entities disclaims beneficial ownership of the shares held by the Funds, except to the extent of their respective indirect pecuniary interests therein.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.